Objective informational resource
for industry professionals

Pharmaceutical Industry review/Фармацевтична галузь, Uncategorized, WEB only

New medicines from Farmak will appear in the UK

The largest Ukrainian manufacturer and exporter of medicines, the pharmaceutical company Farmak, has expanded the range of its own products sold on the UK market.

As a result of successfully passing the checks of the British regulatory authorities, which lasted more than a year, the Ukrainian company registered two new products, which will now be sold in the UK. It is a drug used in MRI (magnetic resonance imaging) and a hormonal drug to stop bleeding. Also since 2021 on this market an anti-inflammatory pain reliever for dental use from Farmak has been selling in the UK.

We have introduced serious medicines to the UK market and we already have a large order for their supply within two years. We cooperate with local partners around the world who track the needs of the market in their region and analyze which drugs Farmak can most successfully compete with in a particular country. This approach helps to transform our Ukrainian company into an international one. And also to show the world the potential of Ukrainian pharmaceuticals in general,” says Volodymyr Kostiuk, Executive Director of Farmak.

During the war, the company, first of all, satisfies the domestic demand of Ukrainian patients, the army, and hospitals, and then prepares products for export. In 2022, Farmak shipped more than 240 types of products to more than 30 countries around the world. Medicines from the Ukrainian manufacturer are sold in the EU countries, Central and South America, the CIS, the Middle East, and Asia. In 2021, Farmak opened a representative office in Vietnam and an office in the United Arab Emirates. The company also plans to open a new plant in Barcelona in 2024. In addition to the production itself, Spain plans to open a multifunctional laboratory complex with an R&D center for the development and testing of new medicines.

https://farmak.ua/

X

error

Подобається наш журнал! Розкажи про нас

RSS
Follow by Email
LinkedIn
LinkedIn
Share
Для копіювання будь-ласка увійдіть в свій аккаунт